Suspecting ATTR Amyloidosis
| Overview / Abstract: |
Amyloid transthyretin (ATTR) amyloidosis is a rare form of amyloidosis. The most dominant organ usually impacted by amyloidosis is the heart, but it can also impact other organs, including the nervous system. Many clinicians who see these patients before they are diagnosed will not be aware of ATTR amyoidosis, nor when to suspect it and how to diagnose this rare condition. On average it takes 2 – 4 years for this treatable condition to be properly diagnosed. This CME/CNE activity is designed to assist clinicians in identifying factors which suggest the need to explore a possible diagnosis of ATTR amyloidosis. |
|
Expiration |
Jul 31, 2021 |
|
Format |
Webinar / Webcast / Video |
|
Credits / Hours |
.5 |
|
Accreditation |
AACME, Inc |
|
Presenters / Authors / Faculty |
Morie A Gertz, MD, MACP, Division of Hematology, Department of Internal Medicine, Mayo Clinic |
|
Activity Specialities / Related Topics |
Cardiology / Cardiovascular, Family Medicine, Neurology |
|
Sponsors / Supporters / Grant Providers |
Akcea Therapeutics and Alnylam Pharmaceuticals |
|
Keywords / Search Terms |
CheckRare Amyloid transthyretin (ATTR) amyloidosis, amyloidosis, Akcea Therapeutics, Alnylam Pharmaceuticals, neurology, cardiology Free CE CME |
|